Interim estimates of 2014/15 influenza vaccine effectiveness in preventing laboratory-confirmed influenza-related hospitalisation from the serious outcomes surveillance network of the Canadian immunization research network, January 2015

Eurosurveillance

Volumn 20, Issue 5, 2015, Pages 1-7

  McNeil, S A ^a   Andrew, M K ^a   Ye, L ^a   Haguinet, F ^b   Hatchette, T F ^a   Elsherif, M ^a   Leblanc, J ^a   Ambrose, A ^a   McGeer, A ^c   McElhaney, J E ^d   Loeb, M ^e   Mackinnon Cameron, D ^a   Sharma, R ^f   Dos Santos, G ^g   Shinde, V ^h  

^a DALHOUSIE UNIVERSITY   (Canada)

^b GSK   (Belgium)

^c MOUNT SINAI HOSPITAL   (Canada)

^d Advanced Medical Research Institute of Canada   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f GLAXOSMITHKLINE   (Canada)

^g Life Sciences Business and Decision   (Belgium)

^h GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CASE CONTROL STUDY; COMORBIDITY; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EFFICACY; FEMALE; HEALTH CARE SURVEY; HOSPITALIZATION; HUMAN; IMMUNIZATION; INFLUENZA A (H3N2); MALE; OUTCOME ASSESSMENT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGE DISTRIBUTION; HEALTH SURVEY; IMMUNOLOGY; INFLUENZA VIRUS A H3N2; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; SEASON; SENTINEL SURVEILLANCE; STATISTICS AND NUMERICAL DATA; VACCINATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CANADA; CASE-CONTROL STUDIES; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POPULATION SURVEILLANCE; SEASONS; SENTINEL SURVEILLANCE; VACCINATION; YOUNG ADULT;

EID: 84922771275     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2015.20.5.21024     Document Type: Article

References (13)

1. Public Health Agency of Canada (PHAC). FluWatch report: January 4 to January 10, 2015 (Week 1). Ottawa: PHAC; 2015. Available from: http://www.phac-aspc.gc.ca/fluwatch/14-15/w01_15/index-eng.php
2. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, et al. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. MMWR Morb Mortal Wkly Rep. 2015;64(1):10-5. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6401a4.htm?s_ cid=mm6401a4_w PMID:25590680
3. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2014/15 vaccine effectiveness against influenza A(H3N2) from Canada’s Sentinel Physician Surveillance Network, January 2015. Euro Surveill. 2015;20(4):pii=21022. Available from: http://www.eurosurveillance.org/Viewarticle.aspx?ArticleId=21022
4. National Advisory Committee on Immunization. Statement on seasonal influenza vaccine for 2014-2015. Ottawa: Public Health Agency of Canada; 2014. Available from: http://www.phac-aspc.gc.ca/naci-ccni/assets/pdf/flu-grippe-eng.pdf
5. Centers for Disease Control and Prevention (CDC). CDC health advisory regarding the potential for circulation of drifted influenza A(H3N2) viruses. Centers for Disease Control and Prevention Health Alert Network. Atlanta, GA: CDC: 3 Dec 2014. Available from: http://emergency.cdc.gov/HAN/han00374.asp
6. McNeil S, Shinde V, Andrew M, Hatchette T, Leblanc J, Ambrose A, et al. Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014. Euro Surveill. 2014;19(9):20729. http://dx.doi.org/10.2807/1560-7917.ES2014.19.9.20729. PMID:24626207
7. Kelly HA, Sullivan SG, Grant KA, Fielding JE. Moderate influenza vaccine effectiveness with variable effectiveness by match between circulating and vaccine strains in Australian adults aged 20-64 years, 2007-2011. Influenza Other Respi Viruses. 2013;7(5):729-37. http://dx.doi.org/10.1111/irv.12018. PMID:23078073
8. Centers for Disease Control and Prevention (CDC). FluView. 2014-2015 Influenza Season Week 2 ending January 17, 2015. U.S. Virologic Surveillance, Influenza Virus Characterization. Atlanta, GA: CDC. [Accessed 31 Jan 2015]. Available from: http://www.cdc.gov/flu/weekly
9. McNeil SA, Ambrose A, Andrew M, Diaz Mitoma F, Boivin G, Bowie W, et al. Effectiveness of 2012/13 seasonal influenza vaccines in the prevention of influenza-related hospitalization in Canadian adults: A Public Health Agency of Canada/Canadian Institutes of Health Research (PCIRN) Serious Outcomes Surveillance Network Study. Abstract P2-511. Presented at Options for the Control of Influenza VIII, Cape Town, South Africa, 5-10 September, 2013. Available from: http://optionsviii.controlinfluenza.com/optionsviii/assets/File/Options_VIII_Abstracts_2013.pdf
10. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS ONE. 2014;9(3):e92153. http://dx.doi.org/10.1371/journal.pone.0092153. PMID:24667168
11. McNeil SA, Krajden O, Gajic S, Elsherif M, Green K, McGeer A, et al. Performance characteristics of influenza-like-illness case definitions in predicting influenza in hospitalized Canadian adults. Presented at IDWeek 2012, 17-21 Oct 2012, San Diego, CA. Available from: https://idsa.confex.com/idsa/2012/viewsessionpdf.cgi
12. Aoki FY, Allen UD, Stiver HG, Evans GA. The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013. Can J Infect Dis Med Microbiol. 2012;23(4):e79-92. PMID:24294283
13. World Health Organization (WHO). 3rd WHO informal consultation for improving influenza vaccine virus selection. 1 to 3 April 2014, Geneva, Switzerland. Geneva: WHO. [Accessed 15 Jan 2015]. Available from: http://www.who.int/influenza/vaccines/virus/3rdmtg_improve_vaccine_virus_selection/en/